Scanogen has developed a next-generation molecular detection technology and platform instrument for the rapid, accurate, and cost-effective detection of infectious diseases. Our first assay focuses on bloodstream infections in sepsis patients and delivers actionable results in just two hours, compared to the multi-day turnaround of current diagnostic methods. By enabling timely and targeted antimicrobial therapy, our test is poised to significantly improve patient outcomes while reducing the widespread use of inappropriate treatments.

With sepsis care costing more than $50 billion annually in the U.S. alone, our solution has the potential to generate substantial savings for the healthcare system and transform the standard of care. We are now raising a $20 million Series A to advance our clinical studies, scale manufacturing, and prepare for market launch.